Gene therapy for peripheral nervous system diseases

Current Gene Therapy

Volumn 7, Issue 4, 2007, Pages 239-248

  Federici, Thais ^a   Boulis, Nicholas ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Gene therapy; Motor neuron disease; Neuropathy; Neuroprotection; Pain; Peripheral nerve regeneration; Peripheral nervous system; Viral vectors

Indexed keywords

BETA GALACTOSIDASE; BOTULINUM TOXIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; NEUROTROPIC AGENT; PARVOVIRUS VECTOR; PREPROENKEPHALIN; PREPROENKEPHALIN A; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SOMATOMEDIN C; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS;

AMYOTROPHIC LATERAL SCLEROSIS; ANASTOMOSIS; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIABETIC NEUROPATHY; GENE REPLACEMENT THERAPY; GENE THERAPY; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; HYPERALGESIA; MICROSURGERY; MOTOR NEURON DISEASE; NERVE FIBER DEGENERATION; NERVE FIBER REGENERATION; NERVE FIBER TRANSECTION; NERVE GRAFT; NERVE REGENERATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PERIPHERAL NERVE INJURY; PERIPHERAL NEUROPATHY; REVIEW; RNA INTERFERENCE; SPINAL MUSCULAR ATROPHY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

CHARCOT-MARIE-TOOTH DISEASE; DIABETIC NEUROPATHIES; GENE THERAPY; GENETIC VECTORS; HUMANS; MODELS, NEUROLOGICAL; MOTOR NEURON DISEASE; NERVE DEGENERATION; NERVE REGENERATION; PAIN; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; VIRUSES;

EID: 34547805536     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652307781369083     Document Type: Review

References (110)

1. (1994) Classification of Chronic Pain. In: IASP Task Force on Taxonomy, Merksey, H. and Bogduk, N. IASP Press, Seattle, 209-214.
2. Abrams, M. and Widenfalk J. (2005). Emerging strategies to promote improved functional outcome after peripheral nerve injury. Restor. Neurol. Neurosci., 23: 367-382.
3. Acsadi, G., Anguelov, R.A., Yang, H., Toth, G., Thomas, R., Jani, A., Wang, Y., Ianakova, E., Mohammad, S., Lewis, R.A. and Shy, M.E, (2002). Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum. Gene Ther., 13: 1047-1059.
4. Ahmed, Z., Dent, R.G., Suggate, E.L., Barrett, L.B., Seabright, R.J., Berry, M. and Logan, A. (2005). Disinhibition of neurotrophin-induced dorsal root ganglion cell neurite outgrowth on CNS myelin by siRNA-mediated knockdown of NgR, p75NTR and Rho-A. Mol, Cell Neurosci., 28: 509-523.
5. Alisky, J.M. and Davidson, B.L. (2000). Gene therapy for amyotrophic lateral sclerosis and other motor neuron diseases. Hum. Gene Ther., 11: 2315-2329.
6. Apfel, S.C. and Kessler, J.A. (1995). Neurotrophic factors in the therapy of peripheral neuropathy. Baillieres. Clin. Neurol., 4: 593-606.
7. Apfel, S.C. and Kessler, J.A. (1996). Neurotrophic factors in the treatment of peripheral neuropathy. Ciba. Found Symp., 196: 98-108; discussion 108-112.
8. Araki, K., Shiotani, A., Watabe, K., Saito, K., Moro, K. and Ogawa, K. (2006). Adenoviral GDNF gene transfer enhances neurofunctional recovery after recurrent laryngeal nerve injury. Gene Ther., 13: 296-303.
9. Azzouz, M., Ralph, G.S., Storkebaum, E., Walmsley, L.E., Mitrophanous, K.A., Kingsman, S.M., Carmeliet, P. and Mazarakis, N.D. (2004). VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature, 429: 413-417.
10. Blits, B., Boer, G.J. and Verhaagen, J. (2002). Pharmacological, cell, and gene therapy strategies to promote spinal cord regeneration. Cell Transplant., 11: 593-613.
11. Blits, B., Dijkhuizen, P.A., Carlstedt, T.P., Poldervaart, H., Schiemanck, S., Boer, G.J. and Verhaagen, J. (1999). Adenoviral vector-mediated expression of a foreign gene in peripheral nerve tissue bridges implanted in the injured peripheral and central nervous system. Exp. Neurol., 160: 256-267.
12. Boulis, N.M., Noordmans, A.J., Song, D.K., Imperiale, M.J., Rubin, A., Leone, P., During, M. and Feldman, E.L. (2003a). Adeno-associated viral vector gene expression in the adult rat spinal cord following remote vector delivery. Neurobiol. Dis., 14: 535-541.
13. Boulis, N.M., Turner, D.E., Dice, J.A., Bhatia, V. and Feldman, E.L. (1999). Characterization of adenoviral gene expression in spinal cord after remote vector delivery. Neurosurgery, 45: 131-137; discussion 137-138.
14. Boulis, N.M., Turner, D.E., Imperiale, M.J. and Feldman, E.L. (2002). Neuronal survival following remote adenovirus gene delivery. J. Neurosurg. Spine, 96: 212-219.
15. Boulis, N.M., Willmarth, N.E., Song, D.K., Feldman, E.L. and Imperiale, M.J. (2003b). Intraneural colchicine inhibition of adenoviral and adeno-associated viral vector remote spinal cord gene delivery. Neurosurgery, 52: 381-387; discussion 387.
16. Burton, E.A., Fink, D.J. and Glorioso, J.C. (2005). Replication-defective genomic HSV gene therapy vectors: design, production and CNS applications. Curr. Opin. Mol. Ther., 7: 326-336.
17. Campenot, R.B. (1982). Development of sympathetic neurons in compartmentalized cultures. Dev. Biol., 93: 1-12.
18. Campenot, R.B. (1994). NGF and the local control of nerve terminal growth. J. Neurobiol., 25: 599-611.
19. Campenot, R.B. and MacInnis, B.L. (2004). Retrograde transport of neurotrophins: fact and function. J. Neurobiol., 58: 217-229.
20. Chattopadhyay, M., Krisky, D., Wolfe, D., Glorioso, J.C., Mata, M. and Fink, D.J. (2005). HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther., 12: 1377-1384.
21. Chevalier-Larsen, E. and Holzbaur, E.L. (2006). Axonal transport and neurodegenerative disease. Biochim. Biophys. Acta., 1762: 1094-1108.
22. Cope, D.K. and Lariviere, W.R. (2006). Gene therapy and chronic pain. Sci World J., 6: 1066-1074.
23. Cronin, J., Zhang, X.Y. and Reiser, J. (2005). Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther., 5: 387-398.
24. Cui, Q. (2006). Actions of neurotrophic factors and their signaling pathways in neuronal survival and axonal regeneration. Mol. Neurobiol., 33: 155-179.
25. Davar, G., Kramer, M.F., Garber, D., Roca, A.L., Andersen, J.K., Bebrin, W., Coen, D.M., Kosz-Vnenchak, M., Knipe, D.M., Breakefield, X.O. and et al. (1994). Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors. J. Comp. Neurol., 339: 3-11.
26. Deshpande, D.M., Kim, Y.S., Martinez, T., Carmen, J., Dike, S., Shats, I., Rubin, L.L., Drummond, J., Krishnan, C., Hoke, A., Maragakis, N., Shefner, J., Rothstein, J.D. and Kerr, D.A. (2006). Recovery from paralysis in adult rats using embryonic stem cells. Ann. Neurol., 60: 32-44.
27. Desmaris, N., Bosch, A., Salaun, C., Petit, C., Prevost, M.C., Tordo, N., Perrin, P., Schwartz, O., de Rocquigny, H. and Heard, J.M. (2001). Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Mol. Ther., 4: 149-156.
28. Dijkhuizen, P.A., Pasterkamp, R.J., Hermens, W.T., de Winter, F., Giger, R.J. and Verhaagen, J. (1998). Adenoviral vector-mediated gene delivery to injured rat peripheral nerve. J. Neurotrauma., 15: 387-397.
29. Dupuis, L., Muller, A., Meininger, V. and Loeffler, J.P. (2004). Molecular mechanisms of amyotrophic lateral sclerosis: recent contributions from studies in animal models. Rev. Neurol. (Paris)., 160: 35-43.
30. Eisen, A. and Weber, M. (1999). Treatment of amyotrophic lateral sclerosis. Drugs. Aging., 14: 173-196.
31. Fansa, H. and Keilhoff, G. (2003). [Factors influencing nerve regeneration]. Handchir. Mikrochir. Plast. Chir., 35: 72-82.
32. Federici, T. and Boulis, N. (2006). Gene-based treatment of motor neuron diseases. Muscle. Nerve., 33: 302-323.
33. Federici, T. and Boulis, N.M. (2007a). Ribonucleic acid interference for neurological disorders: candidate diseases, potential targets, and current approaches. Neurosurgery., 60: 3-15; discussion 15-16.
34. Federici, T., Kutner, R., Tordo, N., Yang, J., Carlton, E., Boulis, N. and Reiser, J. (2007b). Cell targeting in the CNS using HIV-1-based lentiviral vectors bearing alternative glycoproteins and promoters. Mol. Ther., 15.
35. Federici, T., Liu, J., Teng, Q., Yang, J. and Boulis, N. (2007c). A Means for Targeting Therapeutics to Peripheral Nervous System Neurons with Axonal Damage. Neurosurg., 60: 911-918.
36. Fenrich, K. and Gordon, T. (2004). Canadian Association of Neuroscience review: axonal regeneration in the peripheral and central nervous systems - current issues and advances. Can. J. Neurol. Sci., 31: 142-156.
37. Finiels, F., Ribotta, M.G.y., Barkats, M., Samolyk, M.-L., Robert, J.-J., Privat, A., Revah, F. and Mallet, J. (1995). Specific and efficient gene transfer strategy offers new potentialities for the treatment of motor neuron diseases. Neuroreport, 7: 373-378.
38. Fischer, L., Culver, D., Tennant, P., Davis, A., Wang, M., Castellano-Sanche, A., Khan, J., Polak, M. and Glass, J. (2004). Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol., 185: 232-240.
39. Fleming, J., Ginn, S.L., Weinberger, R.P., Trahair, T.N., Smythe, J.A. and Alexander, I.E. (2001). Adeno-associated virus and lentivirus vectors mediate efficient and sustained transduction of cultured mouse and human dorsal root ganglia sensory neurons. Hum. Gene Ther., 12: 77-86.
40. Frampton, A.R., Jr., Goins, W.F., Nakano, K., Burton, E.A. and Glorioso, J.C. (2005). HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther., 12: 891-901.
41. Fukuda, A., Hirata, H., Akeda, K., Morita, A., Nagakura, T., Tsujii, M. and Uchida, A. (2005). Enhanced reinnervation after neurotization with Schwann cell transplantation. Muscle Nerve, 31: 229-234.
42. Garrity-Moses, M., Teng, Q., Liu, J., Tanase, D. and Boulis, N. (2005a). Neuroprotective adeno-associated virus Bcl-xL gene transfer in models of motor neuron disease. Muscle. Nerve., 32: 734-744.
43. Garrity-Moses, M.E., Teng, Q., Krudy, C., Yang, J., Federici, T. and Boulis, N.M. (2006). X-Linked inhibitor of apoptosis protein gene-based neuroprotection for the peripheral nervous system. Neurosurgery, 59: 172-182; discussion 172-182.
44. Garrity-Moses, M.E., Teng, Q., Liu, J., Tanase, D. and Boulis, N.M. (2005b). Neuroprotective adeno-associated virus Bcl-(x)L gene transfer in models of motor neuron disease. Muscle Nerve, 32: 734-744.
45. Ghadge, G., Roos, R., Kang, U., Wollmann, R., Fishman, P., Kalynych, A., Barr, E. and Leiden, J. (1995). CNS gene delivery by retrograde transport of recombinant replication-defective adenoviruses. Gene Ther., 2: 132-137.
46. Glatzel, M., Flechsig, E., Navarro, B., Klein, M.A., Paterna, J.C., Bueler, H. and Aguzzi, A. (2000). Adenoviral and adeno-associated viral transfer of genes to the peripheral nervous system. Proc. Natl. Acad. Sci. USA, 97: 442-447.
47. Glorioso, J.C. and Fink, D.J. (2004). Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu. Rev. Microbiol., 58: 253-271.
48. Goss, J.R., Goins, W.F., Lacomis, D., Mata, M., Glorioso, J.C. and Fink, D.J. (2002). Herpes simplex-mediated gene transfer of nerve growth factor protects against peripheral neuropathy in streptozotocin-induced diabetes in the mouse. Diabetes, 51: 2227-2232.
49. Hanz, S. and Fainzilber, M. (2006). Retrograde signaling in injured nerve - the axon reaction revisited. J. Neurochem., 99: 13-19.
50. Hao, S., Mata, M., Wolfe, D., Huang, S., Glorioso, J.C. and Fink, D.J. (2003). HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Mol. Ther., 8: 367-375.
51. Hao, S., Mata, M., Wolfe, D., Huang, S., Glorioso, J.C. and Fink, D.J. (2005). Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann. Neurol., 57: 914-918.
52. Head, K.A. (2006). Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern. Med. Rev., 11: 294-329.
53. Henderson, C.E., Phillips, H.S., Pollock, R.A., Davies, A.M., Lemeulle, C., Armanini, M., Simmons, L., Moffet, B., Vandlen, R.A., Simpson, L.C. and et al. (1994). GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science, 266: 1062-1064.
54. Hoke, A. (2006). Mechanisms of Disease: what factors limit the success of peripheral nerve regeneration in humans? Nat. Clin. Pract. Neurol., 2: 448-454.
55. Houlden, H. and Reilly, M.M. (2006). Molecular genetics of autosomal-dominant demyelinating Charcot-Marie-Tooth disease. Neuromolecular. Med., 8: 43-62.
56. Howland, D.S., Liu, J., She, Y., Goad, B., Maragakis, N.J., Kim, B., Erickson, J., Kulik, J., DeVito, L., Psaltis, G., DeGennaro, L.J., Cleveland, D.W. and Rothstein, J.D. (2002), Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A., 99: 1604-1609.
57. Hu, Y., Leaver, S.G., Plant, G.W., Hendriks, W.T., Niclou, S.P., Verhaagen, J., Harvey, A.R. and Cui, Q. (2005). Lentiviral-mediated transfer of CNTF to schwann cells within reconstructed peripheral nerve grafts enhances adult retinal ganglion cell survival and axonal regeneration. Mol. Ther., 11: 906-915.
58. Ide, C. (1996). Peripheral nerve regeneration. Neurosci. Res., 25: 101-121.
59. Kamholz, J., Menichella, D., Jani, A., Garbern, J., Lewis, R.A., Krajewski, K.M., Lilien, J., Scherer, S.S. and Shy, M.E. (2000). Charcot-Marie-Tooth disease type 1: molecular pathogenesis to gene therapy. Brain, 123 (Pt 2): 222-233.
60. Kang, H., Tian, L. and Thompson, W. (2003). Terminal Schwann cells guide the reinnervation of muscle after nerve injury. J. Neurocytol., 32: 975-985.
61. Kaspar, B.K., Llado, J., Sherkat, N., Rothstein, J.D. and Gage, F.H. (2003). Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science, 301: 839-842.
62. Kaspar, B.K., Vich, V., Christian, L., Rothsten, J.D. and Gage, F.H. (2004). AAV Retrograde Transport Potential and Therapeutic Approaches for ALS. Mol. Ther., 9: S18.
63. Kirchmair, R., Tietz, A.B., Panagiotou, E., Walter, D.H., Silver, M., Yoon, Y.S., Schratzberger, P., Weber, A., Kusano, K., Weinberg, D.H., Ropper, A.H., Isner, J.M. and Losordo, D.W. (2007). Therapeutic Angiogenesis Inhibits or Rescues Chemotherapy-induced Peripheral Neuropathy: Taxol- and Thalidomide-induced Injury of Vasa Nervorum is Ameliorated by VEGF. Mol. Ther., 15: 69-75.
64. Kyrkanides, S., Kambylafkas, P., Miller, J.H. and Tallents, R.H. (2004). Non-primate lentiviral vector administration in the TMJ. J. Dent. Res., 83: 65-70.
65. Lee, P., Hohman, T., Cai, F., Regalia, J. and Helke, C. (2001). Streptozotocin-induced diabetes causes metabolic changes and alterations in neurotrophin content and retrograde transport in the cervical vagus nerve. Exp. Neurol., 170: 149-161.
66. Levi-Montalcini, R. (1987). The nerve growth factor 35 years later. Science, 237: 1154-1162.
67. Lewis, M.E., Neff, N.T., Contreras, P.C., Stong, D.B., Oppenheim, R.W., Grebow, P.E. and Vaught, J.L. (1993). Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp. Neurol., 124: 73-88.
68. Makwana, M. and Raivich, G. (2005). Molecular mechanisms in successful peripheral regeneration. FEBS J., 272: 2628-2638.
69. Martini, R. (1997). Animal models for inherited peripheral neuropathies. J. Anat., 191 (Pt 3): 321-336.
70. Martinov, V.N., Sefland, I., Walaas, S.I., Lomo, T., Nja, A. and Hoover, F. (2002). Targeting functional subtypes of spinal motoneurons and skeletal muscle fibers in. vivo by intramuscular injection of adenoviral and adeno-associated viral vectors. Anat. Embryol. (Berl)., 205: 215-221.
71. Mata, M., Chattopadhyay, M. and Fink, D.J. (2006). Gene therapy for the treatment of sensory neuropathy. Expert. Opin. Biol. Ther., 6: 499-507.
72. Matsuoka, N., Ishii, K., Akimoto, M., Hamada, H., Hashimoto, N. and Miyatake, S. (2002). Overexpression of basic fibroblast growth factor and Bcl-xL with adenoviral vectors protects primarily cultured neurons against glutamate insult. Neurosurgery, 50: 857-862; discussion 862-853.
73. Mazarakis, N.D., Azzouz, M., Rohll, J.B., Ellard, F.M., Wilkes, F.J., Olsen, A.L., Carter, E.E., Barber, R.D., Baban, D.F., Kingsman, S.M., Kingsman, A.J., O'Malley, K. and Mitrophanous, K.A. (2001). Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet, 10: 2109-2121.
74. Meunier, A., Latremoliere, A., Mauborgne, A., Bourgoin, S., Kayser, V., Cesselin, F., Hamon, M. and Pohl, M. (2005). Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol. Ther., 11: 608-616.
75. Midha, R., Munro, C.A., Chan, S., Nitising, A., Xu, Q.G. and Gordon, T. (2005). Regeneration into protected and chronically denervated peripheral nerve stumps. Neurosurgery, 57: 1289-1299; discussion 1289-1299.
76. Mikami, M. and Yang, J. (2005). Short hairpin RNA-mediated selective knockdown of NaV1.8 tetrodotoxin-resistant voltage-gated sodium channel in dorsal root ganglion neurons. Anesthesiology., 103: 828-836.
77. Millecamps, S., Mallet, J. and Barkats, M. (2002). Adenoviral retrograde gene transfer in motoneurons is greatly enhanced by prior intramuscular inoculation with botulinum toxin. Hum. Gene Ther., 13: 225-232.
78. Mitsumoto, H. and Bradley, W.G. (1982). Murine motor neuron disease (the wobbler mouse): degeneration and regeneration of the lower motor neuron. Brain., 105 (Pt 4): 811-834.
79. Mitsumoto, H. and Gambetti, P. (1986). Impaired slow axonal transport in wobbler mouse motor neuron disease. Ann. Neurol., 19: 36-43.
80. Miura, H., Oda, K., Endo, C., Yamazaki, K., Shibasaki, H. and Kikuchi, T. (1993). Progressive degeneration of motor nerve terminals in GAD mutant mouse with hereditary sensory axonopathy. Neuropathol. Appl. Neurobiol., 19: 41-51.
81. Natsume, A., Wolfe, D., Hu, J., Huang, S., Puskovic, V., Glorioso, J.C., Fink, D.J. and Mata, M. (2003). Enhanced functional recovery after proximal nerve root injury by vector-mediated gene transfer. Exp. Neurol., 184: 878-886.
82. Oda, K., Yamazaki, K., Miura, H., Shibasaki, H. and Kikuchi, T. (1992). Dying back type axonal degeneration of sensory nerve terminals in muscle spindles of the gracile axonal dystrophy (GAD) mutant mouse. Neuropathol. Appl. Neurobiol., 18: 265-281.
83. Pezet, S., Krzyzanowska, A., Wong, L.F., Grist, J., Mazarakis, N.D., Georgievska, B. and McMahon, S.B. (2006). Reversal of neurochemical changes and pain-related behavior in a model of neuropathic pain using modified lentiviral vectors expressing GDNF. Mol. Ther., 13: 1101-1109.
84. Pradat, P.F. and Mallet, J. (2003). Gene transfer into the central and peripheral nervous system: applications for the treatment of neurodegenerative diseases and peripheral neuropathies. Biotechnol. Genet. Eng. Rev., 20: 49-76.
85. Ralph, G.S., Radcliffe, P.A., Day, D.M., Carthy, J.M., Leroux, M.A., Lee, D.C., Wong, L.F., Bilsland, L.G., Greensmith, L., Kingaman, S.M., Mitrophanous, K.A., Mazarakis, N.D. and Azzouz, M. (2005). Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med., 11: 429-433.
86. Rodrigues Filho, O.A. and Fazan, V.P. (2006). Streptozotocin induced diabetes as a model of phrenic nerve neuropathy in rats. J. Neurosci. Methods., 151: 131-138.
87. Romero, M.I., Rangappa, N., Garry, M.G. and Smith, G.M. (2001). Functional regeneration of chronically injured sensory afferents into adult spinal cord after neurotrophin gene therapy. J. Neurosci., 21: 8408-8416.
88. Schmalbruch, H., Jensen, H.J., Bjaerg, M., Kamieniecka, Z. and Kurland, L. (1991). A new mouse mutant with progressive motor neuronopathy. J. Neuropathol. Exp. Neurol., 50: 192-204.
89. Schroder, J.M. (2006). Neuropathology of Charcot-Marie-Tooth and related disorders. Neuromolecular. Med., 8: 23-42.
90. Shy, M.E. (2006). Therapeutic strategies for the inherited neuropathies. Neuromolecular. Med., 8: 255-278.
91. Shy, M.E., Tani, M., Shi, Y.J., Whyatt, S.A., Chbihi, T., Scherer, S.S. and Kamholz, J. (1995). An actenoviral vector can transfer lacZ expression into Schwann cells in culture and in sciatic nerve. Ann. Neurol., 38: 429-436.
92. Silva, A., Wang, Q., Wang, M., Ravula, S.K. and Glass, J.D. (2006). Evidence for direct axonal toxicity in vincristine neuropathy. J. Peripher. Nerv. Syst., 11: 211-216.
93. Siniscalco, D., de Novellis, V., Rossi, F. and Maione, S. (2005). Neuropathic pain: is the end of suffering starting in the gene therapy? Curr. Drug Targets, 6: 75-80.
94. Sorensen, J., Haase, G., Krarup, C., Gilgenkrantz, H., Kahn, A. and Schmalbruch, H. (1998). Gene transfer to Schwann cells after peripheral nerve injury: a delivery system for therapeutic agents. Ann. Neurol., 43: 205-211.
95. Stoll, G. and Muller, H.W. (1999). Nerve injury, axonal degeneration and neural regeneration: basic insights. Brain. Pathol., 9: 313-325.
96. Storkebaum, E., Lambrechts, D. and Carmeliet, P. (2004). VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays, 26: 943-954.
97. Tam, S.L. and Gordon, T. (2003). Mechanisms controlling axonal sprouting at the neuromuscular junction. J. Neurocytol., 32: 961-974.
98. Teng, Q., Federici, T. and Boulis, N. (2006) Viral Vector Axonal Uptake and Retrograde Transport: Mechanisms and Applications. In: Gene Therapy of the Central Nervous System: From Bench to Bedside, Kaplitt, M. and During, M. Elsevier, pp. 249-267.
99. Tohill, M. and Terenghi, G. (2004). Stem-cell plasticity and therapy for injuries of the peripheral nervous system. Biotechnol. Appl. Biochem., 40: 17-24.
100. Vincent, A.M., Feldman, E.L., Song, D.K., Jung, V., Schild, A., Zhang, W., Imperiale, M.J. and Boulis, N.M. (2004a). Adeno-associated vital-mediated insulin-like growth factor delivery protects motor neurons in. vitro. Neuromolecular. Med., 6: 79-85.
101. Vincent, A.M., McLean, L.L., Backus, C. and Feldman, E.L. (2005). Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASES J., 04-2513fje.
102. Vincent, A.M., Mobley, B.C., Hiller, A. and Feldman, E.L. (2004b). IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol. Dis., 16: 407-416.
103. Weber, R.V. and Mackinnon, S.E. (2005). Bridging the neural gap. Clin. Plast. Surg., 32: 605-616, viii.
104. Wilson, S.P., Yeoman, D.C., Bender, M.A., Lu, Y., Goins, W.F. and Glorioso, J.C. (1999). Antihyperalgesic effects of infection with a pre-proenkephalin-encoding herpes virus. Proc. Natl. Acad. Sci. U. S. A., 96: 3211-3216.
105. Xu, J., Ma, C., Bass, C. and Terwilliger, E.F. (2005). A combination of mutations enhances the neurotropism of AAV-2. Virology, 341: 203-214.
106. Yamamura, J., Kageyama, S., Uwano, T., Kurokawa, M., Imakita, M. and Shiraki, K. (2000). Long-term gene expression in the anterior horn motor neurons after intramuscular inoculation of a live herpes simplex virus vector. Gene Ther., 7: 934-941.
107. Yamashita, S., Mita, S., Arima, T., Maeda, Y., Kimura, E., Nishida, Y., Murakami, T., Okado, H. and Uchino, M. (2001). Bcl-2 expression by retrograde transport of adenoviral vectors with Cn-loxP recombination system in motor neurons of mutant SOD1 transgenic mice. Gene Ther., 8: 977-986.
108. Yamashita, S., Mita, S., Kato, S., Okado, H., Ohama, E. and Uchino, M. (2003). Bcl-2 expression using retrograde transport of adenoviral vectors inhibits cytochrome c-release and caspase-1 activation in motor neurons of mutant superoxide dismutase 1 (G93A) transgenic mice. Neurosci. Lett., 350: 17-20.
109. Yeomans, D.C., Jones, T., Laurito, C.E., Lu, Y. and Wilson, S.P. (2004). Reversal of ongoing thermal hyperalgesia in mice by a recombinant herpesvirus that encodes human preproenkephalin. Mol. Ther., 9: 24-29.
110. Zhang, F. and Lineaweaver, W.C. (2002). Gene transfer with DNA strand technique and peripheral nerve injuries. J. Long. Term. Eff. Med. Implants., 12: 85-96.